Real-Time Access and Interactive Analytics Help Hospitals Guide Quality Improvement Projects and Prepare for CMS Hypoglycemia and Hyperglycemia Measures
WALTHAM, Mass. (April 13, 2023) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the next evolution of GlucoMetrics® to provide new analytics, dashboards and data visualizations that give hospitals and health systems new insight into glycemic outcomes. The enhanced visibility this provides is essential as hospitals prepare for new measures from the Centers for Medicare and Medicaid Services (CMS) on severe hypoglycemia and hyperglycemia that encourage facilities to report metrics starting in early 2024.
“CMS is making it clear that hypoglycemia related to insulin is largely preventable, and early treatment and optimal management of severe hyperglycemia is a priority. But it’s hard to enact and measure this type of change without access to data, or the expertise to turn that data into actionable insights,” said Jordan Messler, MD, Chief Medical Officer at Glytec. “Most hospitals have no way of easily looking across their facility to understand how effectively they’re managing patient blood sugars, and being able to look across an entire health system is even more rare. These enhancements to GlucoMetrics take a significant step towards providing the insight hospitals need to start asking – and answering – important questions.”
GlucoMetrics is powered by data from Glytec’s eGlycemic Management System®(eGMS). Centered on Glucommander®, eGMS is an EHR-integrated, HITRUST certified, cloud-based software solution that supports personalized insulin dosing decision support at the point of care. Providers and nurses who use Glucommander help their patients get into target range faster, stay within tighter parameters and experience fewer insulin-related adverse drug events than patients treated with other protocols.
With significant enhancements to GlucoMetrics, glycemic management committees and hospital leaders now have self-serve access to key performance indicators, trends, and benchmarks related to glycemia treatment across their entire health system. GlucoMetrics is pre-configured with six interactive dashboards to help surface insights at both a macro and micro level. These dashboards include:
- GlucoMetrics Overview - shows trends, performance against internal benchmarks, and comparison to other Glucommander users all in one place - perfect for executives, glycemic management committees, and anyone else who needs to stay informed about GlucoMetrics.
- Treated vs. Untreated – provides insights into patients who are treated using Glucommander, compared to those who are not treated on Glucommander and had several readings >180 mg/dL over the course of at least 2 days.
- Blood Glucose Measurement Timeliness – provides insights into the response time for hourly blood glucose checks for patients on Glucommander IV insulin therapy.
- Patient Stays – provides metrics of patient-stays above, below or in range, important because CMS will be tracking hypoglycemia rates.
- Patient Days – provides metrics of patient-days above, below or in range, important because CMS will be tracking hyperglycemia rates.
- Blood Glucose Values – provides metrics of all blood glucose checks and the proportion above, below or in range.
These dashboards include powerful filters to segment data by time frame, facility, unit, treatment type (IV or subcutaneous) and more, to provide granular details across an entire healthcare system or down to an individual hospital unit level. Users can also customize their experience with saved views and personalized email subscriptions. In addition, they can easily export charts, tables, graphs, and data to Microsoft Excel or PowerPoint for even more sophisticated analysis, further annotations, or distribution.
The actionable insights delivered by GlucoMetrics give hospitals and health systems the data they need to start internal benchmarking. They also give glycemic management teams the clinical indicators they need to identify underperforming areas so they can put processes in place that further improve patient outcomes.
“Glucommander gives our care team the personalized insulin dosing decision support they need to improve patient care at the bedside. And building on that foundation, GlucoMetrics offers our glycemic management committee the visibility that’s essential to understanding the efficacy of our processes, identifying where improvements can be made and ultimately, driving change,” said Sarah Perron, Ph.D., RN, NPD-BC, CMSRN, CNML, Director of Diabetes at BayCare Health System. “These new dashboards and the improved usability of Glytec’s analytics tool have already empowered us to dig further into our data and take action.”
These platform enhancements pave the way for hospitals that partner with Glytec to benchmark against their peers and further fuel their glycemic management steering committees. Through quarterly updates, Glytec will consistently add new features, functionality, and metrics to the GlucoMetrics platform that will provide additional insights to guide and inform quality improvement projects.
Glytec will be demonstrating the capabilities of GlucoMetrics and these new enhancements during the HIMSS Global Health Conference from April 17-21, 2023 at the McCormick Place Convention Center, Chicago, Illinois. For a demo of GlucoMetrics at HIMSS, visit the Glytec booth (#6615 in the North Hall), or contact Glytec to schedule in advance at https://glytecsystems.com/contact-us/.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) and LinkedIn, or visit www.GlytecSystems.com.
fama PR for Glytec
MAR 0000996 Rev 1.0